Sparks commentary

Healthcare

Sparks

SynAct Pharma (STO: SYNACT) launches Phase II trial in dengue
Published by Arron Aatkar, PhD

SynAct Pharma has announced the launch of its exploratory Phase II trial, RESOVIR-2, which has been designed to evaluate the safety and efficacy of resomelagon in patients with dengue, a viral infection. RESOVIR-2 is a randomised and placebo-controlled study, assessing once-daily oral dosing of resomelagon compared to placebo (1:1 randomisation, n=120) as an adjuvant to the standard of care. It has been initiated and is being led by professor Mauro Teixeira, MD, PhD Universidade Federal de Minas Gerais, Belo Horizonte at clinical sites in Brazil. Recruitment, as well as anticipated completion of the trial, will be contingent on the severity of the dengue epidemic.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free